Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
126,115
datasets available to search
ShareScore release 0.9.0
Dataset results
126,115 results for “Patients”
Comparative analysis of two Candida parapsilosis isolates from the patient with a central venous catheter harbouring the Y132F and R398I mutations
<p>This work presents a comparative analysis of 2 clinical isolates of <em>C. parapsilosis</em>; isolated from haemoculture (HC) and central venous catheter (CVC). Both strains harboured Y132F and R398I mutations associated with resistance to fluconazole (FLC). Differences between HC and CVC isolates in terms of virulence, resistance to FLC and lipid distribution were addressed. Expression of the ERG6 and ERG9 genes, lipid analysis, fatty acid composition and lipase activity were assessed by qPCR, thin-layer chromatography/high performance liquid chromatography, gas chromatography and spectrophotometry, respectively. A regulation of the ERG6 and ERG9 genes did not prove any impact on FLC resistance. Analysis of lipid metabolism showed a higher accumulation of lanosterol in both isolates regardless of FLC presence. Additionally, a decreased level in triacylglycerols (TAG) with impact on the composition of total FA was observed for both isolates. Direct impact of the ERG11 mutations to lipid/FA analysis has not been confirmed. The higher lipase activity observed for <em>C. parapsilosis</em> HC isolate could be correlated with the significantly decreased level of TAG. The very close relatedness between both isolates suggests that one isolate was derived from another after the initial infection of the host.</p>
The effectiveness and safety of intensive lipid-lowering with different Rosuvastatin-based regimens in patients at high risk: A nonblind, randomized, controlled trial
<p><span><strong>Background</strong>:</span> <span>Statin alone or nonstatins as add-ons have been introduced to intensive low-density lipoprotein cholesterol (LDL-C) </span><span>lowering</span><span> therapy in patients at high cardiovascular disease (CVD) risk. The purpose of this study was to evaluate the effectiveness and safety of different statin-based regimens for patients at high risk</span><span>.</span></p> <p><span><strong>Methods</strong>:</span> <span>Three hundred patients at high CVD risk were randomly assigned to the statin group</span><span> (Rosuvastatin 20mg/d</span><span>), statin_EZ group</span> <span>(Rosuvastatin 10mg/d + ezetimibe </span><span>10mg/d</span><span>), statin_pcsk group (Rosuvastatin </span><span>10mg/d</span><span> + alirocumab </span><span>75mg/2</span><span>weeks) or combine3 group (Rosuvastatin 10mg/d + ezetimibe 10mg/d + alirocumab 75mg/2weeks)</span><span>.</span> <span>The primary outcome measure was cholesterol levels </span><span>(LDL-C, total cholesterol (TC) triglycerides (TGs), and high-density lipoprotein cholesterol (HDL-C))</span><span> after 24</span><span> weeks of</span><span> follow-up. The secondary outcome measures were safety markers and the proportion of patients who achieved the < 70 mg/dL (1.8 mmol/L) LDL-C target. </span><span>A logistic</span><span> regression model was performed to explore the factors affecting lipid target achievement.</span></p> <p><span><strong>Results</strong>:</span> <span>The TC and LDL-C levels after treatment were significantly different among the four groups</span> <span>(p < 0.05). The levels in both the combine3 group and </span><span>the </span><span>statin_pcsk9 group were significantly lower than </span><span>those in </span><span>the statin group and the statin_EZ group (</span><span>p < 0.05</span><span>), but there was no significant difference between</span><span> the</span><span> combine3 group and </span><span>the </span><span>statin_pcsk9 group. The incidence of adverse events in the four groups was low.</span><span> Body mass index (BMI) and hypertensive status were related to target achievement.</span></p> <p><span><strong>Conclusion</strong>:</span><span> The combination of a statin</span><span> and a PCSK9 inhibitor was safe and more effective for the treatment of high-risk CVD patients, while the addition of </span><span>ezetimibe was</span><span> unable to significantly lower lipid levels any further. The rate of achieving </span><span>the </span><span>target was higher in patients </span><span>with</span><span> hypertension and a low BMI.</span></p>
The role of teriflunomide in Multiple Sclerosis patient: an observational study
<p>Teriflunomide is a drug with immunosuppressive and selective immunomodulatory action, characterized by anti-inflammatory and antiproliferative properties. Several clinical studies have demonstrated the efficacy and safety of this drug in Multiple Sclerosis, estimating a significant improvement in cognitive performance.The aim of our study is to evaluate the effects of teriflunomide by analysing the correlation between brain atrophy and the general cognitive profile and evaluating long-term changes. The effect of teriflunomide was studied in 30 patients with multiple sclerosis and 30 control subjects. Patients underwent a full cognitive profile assessment using the Brief Repeatable Battery of Neuropsychological Tests and a neuroimaging examination with a 3.0 T working scanner.Our results suggested that treatment with teriflunomide could potentially not only slow down the accumulation of microstructural tissue damage in Grey Matter and With Matter, but also better preserve the cognitive profile, particularly by highlighting the benefits in the memory domain. Thanks to drug therapy, brain volume in our patients has remained constant, leading to improvements in memory, indicating teriflunomide as a neuroprotective potential and further strengthening the evidence of a link between loss of brain volume and cognitive impairment.</p>
Effects of COVID-19 in Endocrine Patients: A Cross-Sectional Study.
<p>Abstract: Introduction: Home confinement due to COVID-19 lockdown led to changes in daily<br> routines, including social interactions, as well as restrictions on the possibility of playing sports<br> and eating habits. These changes could have a greater impact on patients suffering from chronic<br> diseases, such as endocrine patients, especially in emotional and behavioral dimensions. Materials<br> and Methods: This study aimed to assess the effects of COVID-19-induced quarantine on daily habits<br> in a group of patients with endocrine disorders, focusing on food consumption, eating habits and<br> sleep during the confinement. Eighty-five endocrine patients were enrolled. A structured interview<br> was administered to investigate socio-demographic information, general medical conditions, and<br> habits adopted during quarantine. All patients underwent the Spielberger State Anxiety Inventory<br> (STAI-Y1) to assess state anxiety. Result: Results showed that subjects mainly had a sedentary lifestyle.<br> We found a significant increase in the number of cigarettes in smokers and in meals consumed during<br> confinement, as well as a high rate of sleep disturbance, especially insomnia. Notably, physical<br> well-being resulted to be a predictive factor (OR = 0.38; 95%CI = [0.95,0.66]), whereas anxiety was a<br> risk factor for sleep disorder (OR = 1.22; 95%CI = [1.10,1.40]), as was working in public and private<br> offices and being a student. Conclusions: Changes in daily habits were likely due to the alterations<br> in routine, resulting in greater boredom and inactivity during the day. In addition, future research<br> should focus on the importance of patient adherence to therapy.</p>
Assessment of Fast-Track pathway in hip and knee replacement surgery by propensity score matching on patient-reported outcomes
<p>This is the dataset accompanying the publication "Assessment of Fast-Track pathway in hip and knee replacement surgery by propensity score matching on patient-reported outcomes" published on the Diagnostics journal.</p>
From Good Science to Good Practice: An Implementation Evaluation of a Home-based Exercise Intervention for COPD Patients
<p>With this study we aimed to comprehensively evaluate the implementation of the home-based HOMEX exercise program in the course of an RCT and the subsequent months, considering the perspective and experience of the involved persons and potential future providers. The results provided guidance to optimize the program and material and to ensure the programs’ long-term sustainability. We provide the following data:</p> <p>Data from patients</p> <ul> <li>Excel File <strong><em>Satisfaction_IG_HOMEX-1_T4.xlsx</em></strong> <ul> <li>Satisfaction questionnaire, 1-year follow-up, intervention group participants (n=53)</li> </ul> </li> <li>Word Files <ul> <li>Transcripts of interviews with 9 selected intervention group participants</li> </ul> </li> </ul> <p>Data from coaches:</p> <ul> <li>Excel File <strong><em>Coaches_Questionnaire_Satisfaction.xlsx</em></strong> <ul> <li>Satisfaction survey, after study end, 12 coaches</li> </ul> </li> </ul> <p> </p> <p><strong>Publication:</strong></p> <p>Cerini T, Kunz R, Dalla Lana K, Radtke T, Polhemus A, Puhan MA, Frei A. Evaluation of the Implementation of a Home-Based Exercise Training Program for People With COPD: A Mixed-Methods Study. <em>Frontiers in Rehabilitation Sciences</em> Front Rehabil Sci; 2021; 2: 743588 / DOI: <a href="https://doi.org/10.3389/fresc.2021.743588"> 10.3389/fresc.2021.743588 </a></p> <p> </p>
Monocentric retrospective cohort of 30,423 COVID-19 patients
<p><span>Population and design: </span><span>Monocentric cohort comparing COVID-19 patients exposed or not exposed to the treatment hydroxychloroquine (HCQ)+azithromycin (AZ) used as a standard of care in our center (Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, Marseille, France). The inclusion period was from 2 March 2020 to 31 December 2021, with a follow-up period of 6 weeks.</span></p> <p><span>Inclusion and exclusion criteria: </span><span>Data included were those of patients ≥ 18 years of age with PCR-proven COVID-19 disease regardless of symptoms (asymptomatic or symptomatic) and treated in our centre, i.e. having had a medical examination by one of the doctors in our centre (Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, Marseille, France) either as outpatients or as inpatients, i.e. hospitalized on the day of the visit in our outpatient unit following evaluation or directly transferred from another medical ward except intensive care unit. The reasons for exclusion were an erroneous patient identification (identity surveillance and duplicates), lack of available medical data, lack of COVID-19 after checking the medical record (including patients without COVID-19 consulting for a post-COVID-19 syndrome), expression of opposition to the use of their medical data for research purposes (in accordance with European General Data Protection Regulation), and data from patients hospitalized in our center after intensive care. Data from COVID-19 outpatients left without medical advice were excluded.</span></p>
Development and validation of metabolic models for predicting survival and immune status of hepatocellular carcinoma patients
<p>Supplementary materials for the article titled “Development and validation of metabolic models for predicting survival and immune status of hepatocellular carcinoma patients”</p>
PASS - A SCORING SYSTEM TO EVALUATE PERSISTENT ACUTE KIDNEY INJURY IN CRITICALLY ILL ADULT ICU PATIENTS
<p>Acute Kidney Injury (AKI) and sepsis is highly prevalent in Intensive Care Units (ICU) and has direct effect on mortality and morbidity. We aimed to evaluate if course and recovery of sepsis-AKI can be predicted using variables collected at the time of admission, and to develop a formula - Persistent AKI Scoring System (PASS) to predict recovery.</p> <p>63 consecutive patients admitted for sepsis-AKI in our ICUs were evaluated over a period of 8 months. Baseline demographic and clinical/laboratory parameters ,including serum creatinine (SCr), Base Excess (BE), Plethysmographic Variability Index (PVI), Caval Index, R wave Variability (RVI), Mean Arterial Pressure (MAP) and Renal Resistivity Index (RI) using renal doppler and need for inotropes were assessed on admission. Patients were managed with standard protocols with fluid resuscitation and other specific therapy. After 6 of hours of fluid resuscitation, hemodynamic status and volume status of the patient was assessed. Patients were classified as Volume Responders or Non-responders depending on hemodynamic stabilization using parameters like MAP. Re- assessment of all the variables was done at 24 hours and 72 hours after admission. The primary outcome was persistent AKI after 72hrs. The secondary outcome was initiation of dialysis and death within 15 days of admission.</p> <p>34 subjects recovered from AKI. 32 patients showed volume response with respect to hemodynamic parameters and 31 patients were non-responders. Response to fluid, MAP at admission, MAP after 6 hours, BE at admission, inotrope requirement, and PVI at admission did not correlate with recovery of AKI. RI, RVI and S Cr at admission significantly correlated with recovery from AKI These 3 parameters were evaluated further to develop the model for predicting recovery from AKI.• Score> 7.8 predicted recovery from AKI with sensitivity of 79.4%, specificity of 72.4%. PPV 81.8% and NPV 76.7%. PASS Score>7.8 had AUROC of 0.85.</p> <p>Multiple logistic regression showed that SCr< 2.36 mg%, RVI > 14.45 and RI < 0.8 on admission correlated with recovery.</p> <p>PASS SCORE Formula was created using the same.</p> <p>CONCLUSION: PASS score can be a simple bed side method to reliably identify salvageable cases of sepsis-AKI, guiding fluid resuscitation and also aiding early referrals from rural to higher centers for better management.</p>
Datasheet of operative prolapsed IVD patients
<p>Datasheet of operative prolapsed IVD patients</p>
Datasheet of non-operative prolapsed IVD patients
<p>Datasheet of non-operative prolapsed IVD patients</p>
The efficacy and safety of meal replacement in patients with type 2 diabetes: a systematic review and meta-analysis
<p>There are supplemental materials for a systematic review and meta-analysis, which studied the efficacy and safety of meal replacement in patients with type 2 diabetes, with a focus on subgroup analysis of variable participant characteristics and MR prescription.</p>
Discrete ankle, knee and hip kinematic parameters for overground walking assessed using inertial sensors in patients with various orthopaedic conditions
<p>The goal of this study was to take the first step towards a diagnosis tool for multi-joint patients by investigating whether it is possible to distinguish subjects respective their disease group solely based on discrete parameters describing their gait pattern.</p> <p>A dataset including patients with unilateral knee or hip osteoarthritis, cervical or lumbar spinal stenosis, and healthy controls was compiled. All participants performed a gait analysis comprising approximately 30 steps at their self-selected preferred walking speed. Spatiotemporal parameters and ankle, knee and hip kinematic trajectories were captured using the inertial sensor system RehaGait® (RehaGait Hasomed GmbH, Magbedurg, Germany). </p> <p>Data of 254 participants were extracted from the laboratory database projects. After checking for duplicates and removing data that did not pass the quality check, 206 participants remained in the final dataset, including 30 patients with unilateral knee ostoarthritis, 20 with unilateral hip osteoarthritis, 43 with lumbar spinal stenosis, 17 with cervical spinal stenosis, and 96 healthy controls. Discrete parameters were extracted for each step using an inhouse algorithm written in Matlab. Mean values for all parameters were calculated for each participant and side and used for further analysis. Sociodemographic data, spatiotemporal parameters, and calculated angles were collected in one dataset, which was then checked for missing values. Missing values of the healthy participants were filled with the mean angle of this group. Missing values in the patient group were filled using the nearest-neighbors method.</p>
How do patients sleep after orthopedic surgery? Changes in objective sleep parameters and pain in hospitalized patients undergoing hip and knee arthroplasty
<p><strong>Aim.</strong> Sleep impairment after hip and knee arthroplasty is multifactorial and still poorly understood and post-operative pain is a potential cause of sleep deprivation or disturbances. The aim of this study was to assess actigraphy-based sleep characteristics and pain scores in patients undergoing knee or hip joint replacement and hospitalized for ten days after surgery. <strong>Methods.</strong> In this observational cohort study, n=20 subjects (11 males and 9 females; age: 64.0±10.39 years old) completed a daily sleep diary and wore the Actiwatch 2 actigraph (Philips Respironics, Portland, OR) to record sleep parameters for 11 consecutive days, starting the day before surgery and ending the 10<sup>th</sup> day after surgery. Subjective scores of pain, by a visual analog scale (VAS), were constantly monitored for the entire experimental protocol. The following evaluation time-points have been considered for the analysis: pre-surgery (PRE), the first (POST1), the fourth (POST4) and the tenth day (POST10) after surgery. A repeated-measures one-way analysis of variance followed by the Tukey-Kramer post hoc tests, or the equivalent nonparametric Friedman test followed by the Dunn’s multiple comparisons, was applied to test differences in sleep and pain among time-points. Test for correlation between mean VAS score and the sleep parameters at each post-operative time point were performed using Pearson’s method. <strong>Results.</strong> Sleep quantity and timing parameters did not differ from PRE to POST10, during the hospitalization. On the contrary, Sleep Efficiency (p=0.006; η<sup>2</sup><sub>p</sub>=0.45, large), Sleep Latency (p=0.039; η<sup>2</sup><sub>p</sub>=0.37, large), Wake After Sleep Onset (p=0.042; η<sup>2</sup><sub>p</sub>=0.34, large), Immobility Time (p=0.005; η<sup>2</sup><sub>p</sub>=0.47, large) and Fragmentation Index (p=0.016; η<sup>2</sup><sub>p</sub>=0.36, large) displayed significant differences. In detail, Sleep Efficiency and Immobility Time significantly decreased at POST1 compared to PRE by 10.8% (p=0.003; ES: 0.9, moderate) and 9.4% (p=0.005; ES: 0.86, moderate) respectively. Overall, all sleep quality parameters showed a trend of constant improvement from POST1 to POST10. VAS scores were higher in the 1<sup>st</sup> day post-surgery (4.58 ± 2.46; p=0.0011 and ES: 1.40, large) compared to POST10 (1.68 ± 1.58) and in POST4 (3.85 ± 2.31) compared to POST10 (-2.18; p=0.0087 and ES: 1.09, moderate). During time, mean VAS showed significant negative correlations with mean Sleep Efficiency (r = -0.71; p=0.021) and mean Immobility Time (r = - 0.83; p=0.003) and a significant positive correlation with Fragmentation Index (r = 0.70; p=0.023), highlighting that high scores of pain were associated with lower overall sleep quality. <strong>Conclusion.</strong> Sleep quantity and timing parameters were stable during the entire hospitalization whereas sleep quality parameters significantly worsened the 1<sup>st</sup> night after surgery compared to the pre-surgery night and, overall, these parameters showed a trend of constant improvement until discharge. Pain scores were at the highest level the 1<sup>st</sup> day after surgery and at the lowest level before discharge with a negative correlation between pain and sleep quality parameters during time. The present study confirms the important impact of surgery on sleep parameters, especially on the first few post-operative days.</p>
Supporting data and analysis for," A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease", main figures PART 1
<p>This deposit contains the supporting records of images and image analysis presented in, " A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease". doi: https://doi.org/10.1101/2022.06.22.497218</p> <p>Associated Zenodo repositories:</p> <table> <thead> <tr> <th scope="col">Description</th> <th scope="col">DOI</th> </tr> </thead> <tbody> <tr> <td>Main figures PART 1, Figure 1,2,3,5</td> <td>10.5281/zenodo.7653239</td> </tr> <tr> <td>Main figures PART 2, Figure 6</td> <td>10.5281/zenodo.7900973</td> </tr> <tr> <td>Supplemental 3DTC figures: S1, S4, S5, S7, S8, S9</td> <td>10.5281/zenodo.7894632</td> </tr> </tbody> </table> <p>Contents:1) a collection of .zip files contains the 3D tissue cytometry files for tissue analyzed in the manuscript doi: https://doi.org/10.1101/2022.06.22.497218. This collection includes the individual analyses for figures 2, 3 and 5. Figure 6 analyses are included in a compansion repository: 10.5281/zenodo.7900973. Contents of zip files by figure contain at a minimum the .obx and a .tif file which includes the segmented objects and associated measurements for use by VTEA (https://vtea.wiki/). Additional files may include gate files (.vtg) or max projections (.tif).</p> <p>2) a collection of zip files containing the RNAScope image files shown in: Figure 1 P,Q. The supplemental figure data for RNAScope. Figures S1,S4 and S5 are found in: 10.5281/zenodo.7894633.</p> <p>Please address any concerns or questions to the authors listed in the deposit or manuscript, doi: https://doi.org/10.1101/2022.06.22.497218</p>
Supporting data and analysis for," A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease", Supplemental 3DTC figures
<p>This deposit contains the supporting records of analysis for 3D cytometry presented in, " A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease". doi: https://doi.org/10.1101/2022.06.22.497218 found in supplemental figures.</p> <p>Contents:</p> <p>1) a collection of .zip files contains the 3D tissue cytometry files for tissue analyzed in the manuscript doi: https://doi.org/10.1101/2022.06.22.497218. This collection includes the individual analyses by figures in the supplemental figure data for 3D tissue cytometry. The main figure data is found at: 10.5281/zenodo.7653239 and 10.5281/zenodo.7900973.</p> <p>2) a collection of zip files containing the RNAScope image files shown in: Figures S1,S4 and S5. The main RNAScope figure data is found at: 10.5281/zenodo.7653239</p> <p>Please address any concerns or questions to the authors listed in the deposit or manuscript, doi: https://doi.org/10.1101/2022.06.22.497218</p>
Figure 1: Extraoral photograph of the patient showing swelling on right side of the jaw.
<p>Figure 1: Extraoral photograph of the patient showing swelling on right side of the jaw.</p>
Development of a Predictive Model for In-Hospital Mortality in COVID-19 Patients Using CAR, IL-6, IL-6/LY, and NLR: A Single-Center Study in Indonesia
<p>Figure 1. ROC Curve of CAR, IL-6, IL-6/LY, and NLR</p> <p> </p> <p>Figure 2. Kaplan Meier curve of (a) CAR (b) IL-6 (c) IL-6/LY (d) NLR blue line represents group above cut off and green one represents group below cut-off</p> <p> </p>
Supporting data and analysis for," A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease", main figures PART 2
<p>This deposit contains the supporting records of analysis for 3D cytometry presented in, " A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease". doi: https://doi.org/10.1101/2022.06.22.497218</p> <p>Contents:</p> <p>1) a collection of .zip files contains the 3D tissue cytometry files for tissue analyzed in the manuscript doi: https://doi.org/10.1101/2022.06.22.497218. This collection includes the individual analyses for figure 6 analyses.</p> <p>Contents of zip files by figure contain at a minimum the .obx and a .tif file which includes the segmented objects and associated measurements for use by VTEA (https://vtea.wiki/). Additional files may include gate files (.vtg) or max projections (.tif).</p> <p> </p> <p>Please address any concerns or questions to the authors listed in the deposit or manuscript, doi: https://doi.org/10.1101/2022.06.22.497218</p> <p> </p>
Ki-67 and Bcl-2 data by flow cytometry in non-malignant bone marrow aspirates and patients with myeloid malignancies
<p>This Data in Brief article displays a flow cytometric assay that was used for the acquisition and analyses of proliferative and anti-apoptotic activity in hematopoietic cells. This dataset includes analyses of the Ki-67 positive fraction (Ki-67 proliferation index) and Bcl-2 positive fraction (Bcl-2 anti-apoptotic index) of the different myeloid bone marrow (BM) cell populations in non-malignant BM, and in BM disorders, i.e. myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The present dataset comprises 1) the percentage of the CD34 positive blast cells, erythroid cells, myeloid cells and monocytic cells, and 2) the determined Ki-67 positive fraction and Bcl-2 positive fraction of these cell populations in tabular form. This allows the comparison and reproduction of the data when these analyses are repeated in a different setting. Because gating the Ki-67 positive and Bcl-2 positive cells is a critical step in this assay, different gating approaches were compared to determine the most sensitive and specific approach. BM cells from aspirates of 50 non-malignant, 25 MDS and 27 AML cases were stained with 7 different antibody panels and subjected to flow cytometry for determination of the Ki-67 positive cells and Bcl-2 positive cells of the different myeloid cell populations. The Ki-67 or Bcl-2 positive cells were then divided by the total number of cells of the respective cell population to generate the Ki-67 positive fraction (Ki-67 proliferation index) or the Bcl-2 positive fraction (Bcl-2 anti-apoptotic index). The presented data may facilitate the establishment and standardization of flow cytometric analyses of the Ki-67 proliferation index and Bcl-2 anti-apoptotic index of the different myeloid cell populations in non-malignant BM as well as MDS and AML patients in other laboratories. Directions for proper gating of the Ki-67 positive and Bcl-2 positive fraction are crucial for achieving standardization among different laboratories. In addition, the data and the presented assay allows application of Ki-67 and Bcl-2 in a research and clinical setting and this approach can serve as the basis for optimization of the gating strategy and subsequent investigation of other cell biological processes besides proliferation and anti-apoptosis. These data can also promote future research into the role of these parameters in diagnosis of myeloid malignancies, prognosis of myeloid malignancies and therapeutic resistance against anti-cancer therapies in these malignancies. As specific populations were identified based on cell biological characteristics, these data can be useful for evaluating gating algorithms in flow cytometry in general by confirming the outcome (e.g. MDS or AML diagnosis) with the respective proliferation and anti-apoptotic profile of these malignancies. The Ki-67 proliferation index and Bcl-2 anti-apoptotic index may potentially be used for classification of MDS and AML based on supervised machine learning algorithms, while unsupervised machine learning can be deployed at the level of single cells to potentially distinguish non-malignant from malignant cells in the identification of minimal residual disease. Therefore, the present dataset may be of interest for internist-hematologists, immunologists with affinity for hemato-oncology, clinical chemists with sub-specialization of hematology and researchers in the field of hemato-oncology.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.